Mechanism of Action
Somatostatin Receptor Subtypes
Lanreotide binds SSTR2 with high affinity and SSTR5 with moderate affinity, the two receptor subtypes predominantly expressed in pituitary somatotrophs and neuroendocrine tumor cells. Receptor coupling to Gi proteins inhibits adenylyl cyclase, reduces intracellular cAMP, activates K+ channels causing membrane hyperpolarization, and blocks voltage-gated Ca2+ channels, collectively suppressing hormone secretion and cell proliferation.
GH/IGF-1 Suppression
In acromegaly (excess GH from pituitary adenoma), lanreotide reduces GH secretion by 50-70% and normalizes IGF-1 in approximately 38-43% of patients. Combined effects reduce the soft tissue overgrowth, organomegaly, metabolic complications, and cardiovascular comorbidities associated with acromegaly.
Antiproliferative Effects in NETs
Beyond secretory control, SSTR2 activation inhibits tumor cell proliferation through cell cycle arrest (G0/G1), pro-apoptotic signaling, and anti-angiogenic effects via reduced VEGF production. The CLARINET trial demonstrated this antiproliferative activity extends progression-free survival even in non-functioning tumors with low secretory activity.
Research Summary
Acromegaly
FDA ApprovedMultiple Phase 3 trials demonstrated GH normalization (<2.5 mcg/L) in 38-43% and IGF-1 normalization in 38-48% of acromegaly patients. Symptom improvements in headache, perspiration, ring size reduction, and soft tissue swelling. Non-inferior to octreotide LAR across comparative studies with easier administration (self-injectable Autogel vs. intramuscular octreotide).
GEP-NETs (CLARINET)
FDA ApprovedCLARINET trial (n=204, non-functioning GEP-NETs): lanreotide 120 mg vs placebo over 96 weeks demonstrated 53% reduction in risk of progression or death (HR 0.47). Median PFS not reached in lanreotide arm vs 18 months placebo. CLARINET FORTE extended data in progressing patients confirmed continued benefit with dose intensification.
Other Indications
Active ResearchResearch exploring lanreotide in thyroid eye disease (Graves' orbitopathy), polycystic kidney disease (DIPAK-1: modest kidney volume reduction), and dumping syndrome. SSTR2-targeted radiopeptide therapy combinations also under investigation.
Calculate your Lanreotide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Acromegaly | 60-120 mg every 28 days; dose adjusted by GH/IGF-1 response | Monthly | Deep subcutaneous (gluteal region) |
| GEP-NET antiproliferative | 120 mg every 28 days (approved dose) | Monthly | Deep subcutaneous |
Autogel prefilled syringe administered by patient or caregiver. Alternate buttock sides each injection.
Interactions
Safety Profile
Most common adverse effects are GI: diarrhea (26-37%), abdominal pain, loose stools, nausea. Gallstone formation is a class effect of somatostatin analogs (18-20% on long-term therapy) due to decreased gallbladder contractility; baseline and periodic gallbladder ultrasound recommended. Injection site reactions are generally mild. Bradycardia and cardiac conduction changes can occur. Impaired glucose regulation (hypoglycemia or hyperglycemia) requires monitoring. Generally well tolerated on long-term monthly therapy.
References
- [1]Caplin ME, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors (CLARINET). N Engl J Med. 2014;371(3):224-233.
- [2]Caron P, et al. Lanreotide Autogel in acromegaly. J Clin Endocrinol Metab. 2004;89(7):3152-3157.